Miriam Martini

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Medicine, Oncology, Pharmacology +13

Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Federica Di Nicolantonio, Miriam Martini, Francesca Molinari et al. · Journal of Clinical Oncology · 2008 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +17

<i>PIK3CA</i> Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

Andrea Sartore‐Bianchi, Miriam Martini, Francesca Molinari et al. · Cancer Research · 2009 · 739 citations

Medicine, Oncology, Pharmacology +17

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer

Andrea Sartore‐Bianchi, Federica Di Nicolantonio, Michele Nichelatti et al. · PLoS ONE · 2009 · 257 citations · Full text

Medicine, Oncology, Pharmacology +17

Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer

Carlotta Costa, Hiromichi Ebi, Miriam Martini et al. · Cancer Cell · 2014 · 218 citations · Full text

Medicine, Cancer Biology, Oncology +8